(Press-News.org) The Montreal Heart Institute (MHI) announces that the COLCORONA study results are published today in The Lancet Respiratory Medicine. The article, which is entitled Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial, concludes that, given the lack of oral therapies available to prevent COVID-19 complications among non-hospitalized patients and the observed benefit of colchicine in patients with a PCR-confirmed diagnosis of COVID-19, this anti-inflammatory drug could be considered as a treatment for those at risk of complications.
"Given the current pandemic, while awaiting collective immunity through vaccination around the world, the need for treatments to prevent COVID-19 complications among patients who contract the disease remains", said Dr. Jean-Claude Tardif, Director of the MHI Research Centre, Professor at the Faculty of Medicine of the Université de Montréal and Principal Investigator of COLCORONA. "Our study showed that colchicine could be used to reduce the risk of complications for some patients with COVID-19."
Colchicine is an inexpensive and readily available anti-inflammatory drug. Orally administered, it is currently prescribed to treat gout, Familial Mediterranean Fever and pericarditis. The COLCORONA study assessed colchicine's potential to reduce the risk of COVID-19-related complications in outpatients over 40 years of age with at least one risk factor for disease progression.
The study's primary efficacy endpoint was the composite of death or hospitalization in patients with COVID-19. Of the 4,488 patients enrolled, including those without a PCR-confirmed diagnosis, the primary endpoint occurred in 4.7% of patients in the colchicine group and 5.8% of those in the placebo group, a non-statistically significant result. For the 4,159 patients with a PCR-based diagnosis of COVID-19, the primary endpoint occurred in 4.6% of patients in the colchicine group and 6.0% of patients in the placebo group, a statistically significant result. Serious adverse events were reported in 4.9% of patients in the colchicine group and 6.3% of those in the placebo group.
Notwithstanding these results, it is recommended that studies such as this one be replicated in non-hospitalized patients with a PCR-confirmed diagnosis of COVID-19. Full study results are available here: http://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00222-8/fulltext.
"The COLCORONA study expands on our knowledge of the role of oral, cheap and widely available repurposed drugs such as colchicine to treat people early on to prevent serious complications of COVID-19 and can help practitioners and their patients make informed treatment decisions," said Yves Rosenberg, M.D., M.P.H., chief of the Atherothrombosis and Coronary Artery Disease Branch at the National Heart, Lung, and Blood Institute, part of the United States National Institutes of Health.
COLCORONA (NCT04322682) is a randomized, double-blinded, placebo-controlled, home-based clinical trial. It was conducted in Canada, the United States, Europe, South America, and South Africa. The study included 4,488 non-hospitalized patients over 40 years of age with COVID-19 at the time of inclusion, with at least one identified risk factor for COVID-19 complications (e.g., diabetes, hypertension, known respiratory disease, obesity). Patients were randomized to receive colchicine (0.5 mg twice daily for three days and once daily after) or placebo for 30 days.
INFORMATION:
The Montreal Health Innovation Coordinating Centre (MHICC) at the MHI coordinated COLCORONA, which was funded by the Quebec government, the National Heart, Lung, and Blood Institute of the U.S. National Institutes of Health (NIH), Montreal philanthropist Sophie Desmarais, and the COVID-19 Therapeutics Accelerator, an initiative launched by the Bill & Melinda Gates Foundation, Wellcome and Mastercard. Montreal-based CGI, Dacima and Pharmascience were also collaborators in the study.
About the Montreal Heart Institute
Founded in 1954, the Montreal Heart Institute constantly aims for the highest standards of excellence in the cardiovascular field through its leadership in clinical and basic research, ultra-specialized care, professional training, and prevention. It houses the largest cardiology research center in Canada, the largest cardiovascular prevention center in the country, and the largest cardiovascular genetics center in Canada. The Institute is affiliated with the Université de Montréal and has more than 2,000 employees, including 245 doctors and more than 85 researchers. icm-mhi.org
About the Montreal Health Innovations Coordinating Center (MHICC)
The Montreal Health Innovations Coordinating Center (MHICC) is a leading academic clinical research organization and an integral part of the Montreal Heart Institute (MHI). The MHICC possesses an established network of collaborators in over 4,500 clinical sites in more than 35 countries. It has specific expertise in precision medicine, low-cost high-quality clinical trials, and drug repurposing. mhicc.org
About Pharmascience
Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec. With its head office located in Montreal and its 1,500 employees, Pharmascience Inc. is a private pharmaceutical company with deep roots in Canada, and whose global reach spans across more than 60 countries. Ranked 47th among the top 100 Canadian investors in Research and Development (R&D), thanks to $49,5 million investment in 2018, Pharmascience Inc. is one of the largest manufacturer of generic drugs in the country. pharmascience.com
About CGI
Founded in 1976, CGI is one of the world's largest information technology (IT) and management consulting firms. From hundreds of locations around the world, CGI offers a complete portfolio of services and solutions: strategic IT and management consulting services, systems integration services, intellectual property solutions as well as IT and business process management services in delegated mode. cgi.com/canada
About Dacima
Founded in 2006, Dacima Software Inc. is a leading innovator in Electronic Data Capture (EDC) software for clinical research. Dacima's EDC software, Dacima Clinical Suite, is a fully feature EDC software application with integrated modules for patient randomization (IWRS), supply management, ePRO, eDiary, medical coding and eConsent. Dacima's flexible and highly configurable EDC platforms allow for the design of all types of study designs including clinical trials, patient registries, observational studies and web surveys through an intuitive user-friendly web interface. dacimasoftware.com
About the COVID-19 Therapeutics Accelerator
The Therapeutics Accelerator is an initiative launched by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard with support from public and philanthropic donors to speed up the response to the COVID-19 pandemic by identifying, assessing, developing, and scaling up treatments. Its partners are committed to equitable access, including making products available and affordable in low-resource settings. http://www.therapeuticsaccelerator.org
Multiple scientific studies show switching completely to vaping with high-quality products has reduced health risks compared to smoking, contrary to many consumer beliefs
Study data indicates that vaping products can provide an alternative for smokers who would not otherwise quit
Review supports the important role for vaping products in Tobacco Harm Reduction
Reinforces the importance of BAT's unique consumer-centric model and how we are reducing the health impact of our business and building A Better Tomorrow™ through our multicategory approach
To mark World Vape Day, BAT has today published a comprehensive review of the scientific evidence ...
In a world first, scientists from the University of Sussex have recorded blood oxygen levels in the hippocampus and provided experimental proof for why the area, commonly referred to as 'the brain's memory centre', is vulnerable to damage and degeneration, a precursor to Alzheimer's disease.
To understand why this region is so sensitive, the University of Sussex researchers, headed up by Dr Catherine Hall from the School of Psychology and Sussex Neuroscience, studied brain activity and blood flow in the hippocampus of mice. The researchers then used simulations to predict that the amount of oxygen supplied to hippocampal neurons furthest from blood vessels is only just enough for the cells to keep working normally.
Dr Catherine ...
The basis for this new take on the classification was laid in 1985, when John Long attributed a fossil tooth plate to a new species, Edaphodon eyrensis. The species was named after Lake Eyre, near which the tooth was found in 1978.
Asscoiate Professor Evgeny Popov had his doubts about the attribution. However, he had to study the fossil personally to advance his theory. The opportunity presented itself during a trip to Australia in 2010. The tooth plate was stored in a museum in Adelaide, South Australia.
"I didn't plan to go there, but I was able to negotiate a temporary ...
A research group from Aarhus University has developed a special biocompatible electrode for electrical muscle stimulation that the group has integrated and 3D-printed onto medical support stockings.
In the winter 2020/2021, the stockings were tested on hospitalised Covid patients. The studies were completed in March, but apart from a case study (Danish Medical Journal) data have not yet been published. However, the project group reveal that the results are very promising.
The stockings were tested on 16 Covid-19 patients who agreed to try the support stocking during their hospitalisation. The participants were hospitalised for five to seven days and were given a support stocking on each leg, but only ...
The countries around the Baltic Sea do not respect their binding international agreement to reduce agricultural pollution of the marine environment. Despite farming activities being the single most important source of nutrient pollution to the Baltic Sea.
An international research team presents evidence on these circumstances in a recent scientific article in the journal Ambio, published by the Royal Swedish Academy of Sciences.
The countries made a commitment 20 years ago to implement 10 specific reduction measures in their national legislation on agricultural pollution - e.g. featuring minimum storage capacity for manure and regulations on animal densities.
Now the researchers' study of legislations and regulations in place at national level, to address ...
AMES, Iowa - Researchers have developed new types of materials that combines two or three types of nanoparticles into structures that display fundamental new properties such as superfluorescence.
"The whole goal of this research is to make new materials with new properties and/or exotic new structures," said Alex Travesset, an Iowa State University professor of physics and astronomy and an associate scientist for the U.S. Department of Energy's Ames Laboratory. "Those materials are made of very tiny materials, nanoparticles, and lead to properties not shared by more traditional materials made of atoms and molecules."
In this case, an international research team is combining perovskite nanocubes - tiny crystals with useful electrical or optical properties ...
Metal-organic framework compounds (MOFs) consist of inorganic and organic groups and are characterised by a large number of pores into which other molecules can be incorporated. MOFs are therefore interesting for many applications, for example for the storage of gases, but also for substance separation, sensor technology or catalysis. Some of these MOF structures react to different guest molecules by changing their structures. They are thus considered switchable.
One of these is "DUT-8", a material that has now been studied at the MX beamlines of BESSY II. "MOF crystals can be analysed very well at the MX beamlines," says HZB expert Dr. Manfred Weiss, who heads the MX team. ...
A breast cancer therapy that requires just one shot of radiotherapy is as effective as traditional radiotherapy, and avoids potential damage to nearby organs, according to a paper by UCL experts.
The results, published in the British Journal of Cancer, mean that eight out of ten patients who receive the treatment, TARGIT-IORT, will not need a long course of post-operative external beam radiotherapy (EBRT). These results strengthen and expand previously published outcomes.
Patients who received the treatment are less likely to go on to experience fatal cardiovascular disease such as heart attacks, lung problems or other cancers. As well as avoiding scattered radiation from EBRT that can damage nearby vital organs, delivering TARGIT-IORT during the lumpectomy procedure seems to ...
Much of human invention and innovation has been the result of our discovery and replication of natural phenomena, from birds serving to inspire human flight, to whales allowing us to dive deep into the ocean with submarines. For the first time ever, researchers have captured at the nanometer level the gliding machinery of the bacterium Mycoplasma mobile. Their findings were published in mBio. This brings us closer to understanding the origin and operating principle of motility, which could serve as a basis for the next generation of nanoscale devices and pharmaceuticals.
"My lab has been studying the molecular nature of bacteria from the Mycoplasma genus for years", ...
(Bethesda, MD - May 25, 2021) A new study published in Nature Scientific Reports has found that Methylene Blue, a century old medicine, has the potential to be a highly effective, broad-spectrum UV irradiation protector that absorbs UVA and UVB, repairs ROS and UV irradiation induced DNA damages, and is safe for coral reefs. The study suggests that Methylene Blue could become an alternative sunscreen ingredient that supports the environment and protects human skin health.80% of today's sunscreens use Oxybenzone as a chemical UV blocker, despite multiple studies that have shown it expedites the destruction of coral reefs. Several states and countries have now banned the use of Oxybenzone and its derivatives to stop the devastating ...
